Treatment of (long-standing) persistent atrial fibrillation (AF) remains cumbersome and the surgical (epicardial) approach seems to be the most effective. Still, however a significant amount of failures exist which is mostly due to incompleteness of the surgical ablation lines. Checking, and if necessary additional ablation, of these lines afterwards endocardially by the cardiologist (the so-called serial hybrid approach) could overcome this problem.

Brief Title

Serial Hybrid Atrial Fibrillation Ablation

Official Title

Serial Hybrid Atrial Fibrillation Ablation

Brief Summary

Treatment of (long-standing) persistent atrial fibrillation (AF) remains cumbersome and the<br /> surgical (epicardial) approach seems to be the most effective. Still, however a significant<br /> amount of failures exist which is mostly due to incompleteness of the surgical ablation<br /> lines. Checking, and if necessary additional ablation, of these lines afterwards<br /> endocardially by the cardiologist (the so-called serial hybrid approach) could overcome this<br /> problem.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.

Inclusion Criteria:

  -  patients are screened and accepted for pulmonary vein isolation according to the
     current guidelines

  -  long standing persistent or persistent AF as defined in the guidelines

  -  left atrial size needs to be more than >46 mm on long axis or >35 cc/m2

  -  CHADSVASC score should be more than 0 as an indicator of a substantial substrate for
     atrial fibrillation.

Exclusion Criteria:

  -  Significant coronary artery disease has to be excluded as a trigger for AF by means of
     cardiac CT, if necessary a coronary angiogram will be performed.

  -  Previous PVI ablation (epicardial or endocardial) or cardiac surgery.

  -  Significant valvular disease present on echo.

  -  Concomitant cardiac surgery needed.